home

Home> Industry News >R&D >Main Body

Industry News

Shire's OPUS-3 Phase 3 Trial with Lifitegrast Meets Primary and Key Secondary Endpoints, Significantly Reducing Patient-Reported Symptoms for Dry Eye Disease

2015-10-28 17:54

Source：Pipelinereview

Read：491 Favorite 0

Share

相关阅读

You may interest

Copyright©2020 药渡经纬信息科技（北京）有限公司电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |（京）-经营性-2015-0023（互联网药品信息服务资格证书）

: 药渡APP

: 微信二维码